Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
04/10/2007 19:25
PR Newswire
CALGARY, Canada, October 4 /PRNewswire/ -- Ms. Mary Ann Dillahunty, Vice President, Intellectual Property of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate
overview of the Company at BIO InvestorForum 2007 on Thursday, October 11
at 12 p.m. PT. The conference will be held at the Palace Hotel in San
Francisco from October 9-11, 2007.
A live audio link to the webcast presentation is available on the
company's website at http://www.oncolyticsbiotech.com. It is recommended that
listeners log on 15 minutes in advance of the presentation to register and
download any necessary software.
An audio replay will be accessible approximately one hour following the
presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of Phase I and Phase II
human trials using REOLYSIN(R), its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For
further information about Oncolytics, please visit
http://www.oncolyticsbiotech.com
The presentation and webcast times are subject to change. This release
and the presentation related thereto contain forward-looking statements
which involve known and unknown risks, delays, uncertainties and other
factors not under the Company's control and which may cause actual results,
performance or achievements of the Company to be materially different from
the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the
efficacy of REOLYSIN(R) as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals and uncertainties related to
the regulatory process. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update
these forward-looking statements.
For further information: For Canada: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr, NW, Calgary, Alberta, T2N 1X7, Tel: +1-403-670-7377, Fax: +1-403-283-0858, cathy.ward@oncolytics.ca; For Canada: The Equicom Group, Nick Hurst, 325-300 5th Ave., SW, Calgary, Alberta, T2P 3C4, Tel: +1-403-538-4845, Fax: +1-403-237-6916, nhurst@equicomgroup.com; For United States: The Investor Relations Group, Erika Moran, 11 Stone St, 3rd Floor, New York, NY, 10004, Tel: +1-212-825-3210, Fax: +1-212-825-3229, emoran@investorrelationsgroup.com